Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada
NCT04397328 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · PHASE3 · withdrawn · last registry update 2025-09-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study Withdrawn” | – | Registry record, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TLR7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-09Results posted on the registry: EMD Serono Research & Development Institute, Inc., M5049 dose + Placebo (NCT05650567)
- 2026-09-09Also stopped (terminated): EMD Serono Research & Development Institute, Inc., M5049 dose + Placebo (NCT05650567)
- 2026-09-08Also stopped (withdrawn): Apsen Farmaceutica S.A., Hydroxychloroquine Sulfate + Hydroxychloroquine Sulfate + Azythromycin (NCT04361461)
- 2026-09-02Also stopped (suspended): National Institute of Allergy and Infectious Diseases (NIAID), ChAdOx1.tHIVconsv1 + ChAdOx1.HIVconsv62 (NCT06071767)
- 2026-08-20Results posted on the registry: VA Office of Research and Development, Hydroxychloroquine + Matching Placebo (NCT03636152)
- 2026-08-05Results posted on the registry: Massachusetts General Hospital, Capecitabine + Hydroxychloroquine (NCT01494155)
- 2026-07-28Phase 3 first posted: Ain Shams University, Nicorandil Oral Tablet + Placebo (NCT07730723)
- 2026-07-21Results posted on the registry: HonorHealth Research Institute, Paclitaxel protein bound + Gemcitabine (NCT04669197)
- 2026-07-20Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Placebo for VIB4920 + VIB4920 with TNFi (NCT05306353)
- 2026-07-20Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Placebo for VIB4920 + VIB4920 with TNFi (NCT05306353)
- 2026-06-18Phase 3 first posted: Chinese SLE Treatment And Research Group, Sirolimus + Placebo (NCT07657793)
- 2026-06-12Also stopped (terminated): Northwestern University, Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab (NCT05576896)
- 2026-05-19Also stopped (withdrawn): Nicholas Carlson, Hydroxychloroquine (NCT05110651)
- 2026-05-14Also stopped (terminated): University of Utah, Hydroxychloroquine + Trametinib (NCT03825289)
- 2026-04-29Also stopped (terminated): Guy's and St Thomas' NHS Foundation Trust, Hydroxychloroquine + Placebo (NCT04316494)
- 2026-04-14Also stopped (terminated): University Hospital, Rouen, Hydroxychloroquine + placebo (NCT02595346)
- 2026-04-13Also stopped (terminated): Cancer Trials Ireland, Trametinib + Hydroxychloroquine (NCT05518110)
- 2026-04-06Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Plaquenil 200Mg Tablet + Placebo oral tablet (NCT04275778)
- 2026-03-27Also stopped (terminated): Incannex Healthcare Ltd, IHL-675A + Cannabidiol (NCT05942911)
- 2026-03-03Also stopped (suspended): National Institute of Allergy and Infectious Diseases (NIAID), CH505 TF chTrimer + 3M-052-AF (NCT06680479)
- 2026-02-27Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), CH505 TF chTrimer + 3M-05-AF (NCT04915768)
- 2026-02-06Also stopped (terminated): Queen's Medical Center, Hydroxychloroquine (NCT04345692)
- 2026-01-23Results posted on the registry: Emory University, Gemcitabine + Hydroxychloroquine (NCT04524702)
- 2026-01-21Phase 3 first posted: EMD Serono Research & Development Institute, Inc., Enpatoran + Placebo (NCT07355218)
- 2026-01-16Results posted on the registry: Gilead Sciences, Vesatolimod + VRC07523LS (NCT05281510)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision